Quarterly report pursuant to Section 13 or 15(d)

Organization and Nature of Operations

Organization and Nature of Operations
9 Months Ended
Sep. 30, 2022
Organization and Nature of Operations [Abstract]  



Brain Scientific Inc. (the “Company”), was incorporated under the laws of the state of Nevada on November 18, 2013 under the name All Soft Gels Inc. On October 1, 2021, the Company acquired Piezo Motion Corp (“Piezo”), a privately held Delaware corporation formed in January 2020. Upon completion of the acquisition, Piezo is treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of Piezo. The Company has two lines of operations. The MemoryMD subsidiary group is involved in cloud computing, data analytics and medical device technology in the NeuroTech and brain monitoring industries, seeking to commercialize its EEG devices and caps. The Piezo subsidiary group is focused on the ultrasonic standing wave-type piezo motor technology for rotary and linear motion and has experience in the research and development, as well as the manufacturing of piezo motors for high-tech industries across the globe. The Company is headquartered in Sarasota, Florida.


Reverse Merger and Corporate Restructure


On June 11, 2021, the Company entered into a merger agreement (the “Merger Agreement”) with Piezo and BRSF Acquisition Inc. to acquire Piezo (the “Acquisition”). The transactions contemplated by the Merger Agreement were consummated on October 1, 2021 and, pursuant to the terms of the Merger Agreement, all outstanding shares of Piezo were exchanged for 29,520,454 shares of the Company’s common stock and Piezo became the Company’s wholly owned subsidiary.


The Merger was effected pursuant to the Merger Agreement. The Merger was accounted for as a reverse merger whereby Piezo was the acquirer for accounting purposes. Piezo is considered the acquiring company for accounting purposes as upon completion of the Merger, Piezo’s former stockholders held a majority of the voting interest of the combined company.


Pursuant to the Merger, the Company issued shares of its common stock to Piezo’s stockholders, at an exchange ratio of 2.93 shares of the Company’s common stock.


All references to common stock, share and per share amounts have been retroactively restated to reflect the reverse recapitalization as if the transaction had taken place as of the beginning of the earliest period presented.


Acquisition Accounting 


The fair value of Brain Scientific assets acquired and liabilities assumed was based upon management’s estimates assisted by an independent third-party valuation firm.


The following table summarizes the allocation of purchase price of the acquisition:


Tangible Assets Acquired:      
Net working capital   $ (1,186,622 )
Right of use asset     40,093  
Lease liability     (46,970 )
Net Tangible Assets Acquired   $ (1,193,499 )
Intangible Assets Acquired:        
Licenses and trademarks        
Brain Scientific Trade Name     133,000  
MemoryMD Trade Name     504,000  
Neurocap Trade Name     188,000  
Neuro EEG Trade Name     11,000  
Patent products        
NeuroCap Developed Technology     10,242,000  
NeuroEEG Developed Technology     35,000  
Net Intangible Assets Acquired   $ 11,113,000  
Total Fair Value of Assets Acquired   $ 9,919,501  
Fair value of equity received     7,240,222  
Liabilities assumed     2,987,152  
Loans forgiven     605,311  
Total consideration   $ 10,832,685  
Goodwill   $ 913,184  


Unaudited Interim Financial Information


The Company has prepared the accompanying condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These consolidated financial statements are unaudited and, in the Company’s opinion, include all adjustments, consisting of normal recurring adjustments and accruals necessary for a fair presentation of its balance sheets, operating results, and cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for 2022. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been omitted in accordance with the rules and regulations of the SEC. These consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes.